Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia

Abstract excerpt

Despite recent advances in the cure rate of acute lymphoblastic leukaemia (ALL), the prognosis for patients with relapsed ALL remains poor. Here we identify FOXM1 as a candidate responsible for an aggressive clinical course. We show that FOXM1 levels peak at the pre-B-cell receptor checkpoint but are dispensable for normal B-cell development. Compared with normal B-cell populations, FOXM1 levels are 2- to 60-fold...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to FOXO transcription factor regulation
• Share to Pancreatic function and diabetes
• Share to Signaling Pathways in Disease